NCT03406858 Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Status COMPLETED Phase PHASE2
NCT03405792 Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03402880 ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Status WITHDRAWN Phase PHASE2
NCT03401853 Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Status TERMINATED Phase PHASE2
NCT03397654 Study of Pembrolizumab Following TACE in Primary Liver Carcinoma Status COMPLETED Phase PHASE1/PHASE2
NCT03396952 Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma Status COMPLETED Phase PHASE2
NCT03396926 Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer Status COMPLETED Phase PHASE2
NCT03396497 Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Status UNKNOWN Phase PHASE1
NCT03396471 Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary Status TERMINATED Phase PHASE2
NCT03396445 Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) Status COMPLETED Phase PHASE1
NCT03395847 Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma Status COMPLETED Phase EARLY_PHASE1
NCT03393845 Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03390504 A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03385226 A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03384836 Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery Status SUSPENDED Phase PHASE1/PHASE2
NCT03383094 Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03382899 Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT03382600 Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) Status COMPLETED Phase PHASE2
NCT03380871 A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer Status COMPLETED Phase PHASE1
NCT03374488 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Status COMPLETED Phase PHASE3